FDA approves additional Daptacel dose
The FDA has licensed Daptacel (diphtheria and tetanus toxoids and acellular pertussis [DTaP] vaccine, from Sanofi Pasteur) to be administered as a fifth consecutive vaccine dose for children 4-6 years of age for the prevention of diphtheria, tetanus and pertussis. This approval is supported by a clinical trial involving 487 children wherein 93% experienced a booster response to each of the pertussis components and 100% achieved antibody responses against both tetanus and diphtheria infection. None of the children involved in the study withdrew as a result of an adverse event or contraindication.
Daptacel is indicated for active immunization against diphtheria, tetanus, and pertussis in patients 6 weeks through 6 years of age.
For more information call (800) VACCINE or visit www.daptacel.com.